MAIA Biotechnology held its 2026 Annual Meeting of stockholders on May 21, 2026. A quorum was established with 37,547,754 shares represented, accounting for 61.88% of the 60,671,491 outstanding shares. Stockholders re-elected Louie Ngar Yee and Steven Chaouki as Class I directors for three-year terms expiring in 2029. Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for fiscal year 2026.